Core Viewpoint - The announcement details the implementation of the 2024 Restricted Stock Incentive Plan by Guangzhou Maipu Medical Technology Co., Ltd, highlighting the first grant of restricted stocks and the conditions for their vesting [1][2][4]. Summary by Sections Incentive Plan Overview - The 2024 Restricted Stock Incentive Plan involves granting a total of 576,000 restricted shares, representing approximately 0.87% of the company's total share capital as of the plan's announcement date [2]. - The initial grant consists of 461,000 shares, accounting for about 0.70% of the total share capital, while 115,000 shares are reserved, representing 0.17% [2]. Granting and Vesting Conditions - The plan includes 28 core technical and business personnel as recipients, excluding independent directors and major shareholders [2]. - The vesting schedule is structured into three phases: 30% after 12 months, 30% after 24 months, and 40% after 36 months from the grant date [6][7]. Performance Assessment - The performance assessment for the incentive plan is based on annual revenue growth targets for the years 2024 to 2026, with specific percentage goals set for each year [9][10]. - The company must achieve a minimum revenue growth rate to trigger the vesting of shares, with the first year's target set at 23% [9]. Approval and Compliance - The plan has undergone necessary approvals from the board and supervisory committee, confirming that the vesting conditions have been met for the first grant [12][17]. - Legal opinions affirm that the plan complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [18][19]. Adjustments and Pricing - The grant price for the restricted shares has been adjusted from 22.80 RMB to 22.20 RMB per share due to corporate actions such as cash dividends [15].
迈普医学: 关于2024年限制性股票激励计划首次授予部分第一个归属期归属条件成就的公告